<![CDATA[Debate: Class Effect Versus Meaningful Differences Among BCMA Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma]]>

Summary

Cancer Network presented a FACE-OFF debate discussing whether currently available BCMA bispecific antibodies should be considered a therapeutic class or whether meaningful clinical differences exist among individual agents for treating relapsed/refractory multiple myeloma.